All In Biotech

NDA 209377 · Am Regent

Zinc Sulfate

Zinc Sulfate · Intravenous

Last checked: Nov 20, 2026Latest source record: Oct 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 18, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

414

101 Phase 3, 28 recruiting

FAERS reports

2,864

2,169 serious, 396 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 1, 2020.

Zinc Sulfate Injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Zinc Sulfate Injection is a trace element indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: Zinc is an essential trace element. Zinc functions as a cofactor of various enzymes including DNA polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding, such as folding of “Zinc finger” motif that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of substrates of carbonic anhydrase in erythrocyte. Also, zinc is a signaling mediator modulating multiple signaling pathways.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 18, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • ZINC SULFATE · ZINC SULFATE EQ 10MG BASE/10ML (EQ 1MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • ZINC SULFATE · ZINC SULFATE EQ 30MG BASE/10ML (EQ 3MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • ZINC SULFATE · ZINC SULFATE EQ 25MG BASE/5ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Zinc" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea226
  • fatigue185
  • nausea177
  • off label use158
  • death156
  • pain147
  • vomiting145
  • dyspnoea140
  • pyrexia131
  • headache111
  • asthenia103
  • pneumonia101

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200520
200625
200726
200821
200945
201044
201148
2012225
201344
201463
201592
2016156
2017114
2018152
2019158
2020373
2021231
2022262
2023193
2024163
2025210
2026151

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,698 on PubMed

Sponsor: Am Regent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.